Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer

BACKGROUND: Tamoxifen is the cornerstone of adjuvant therapy for hormone receptor-positive breast cancer. Despite its efficacy, limited drug sensitivity and endocrine resistance remain the important clinical challenges. The main objective of this study was to investigate fatostatin, which was found...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Liu, Ying, Zhang, Ning, Zhang, Hanwen, Wang, Lijuan, Duan, Yi, Wang, Xiaolong, Chen, Tong, Liang, Yiran, Li, Yaming, Song, Xiaojin, Li, Chen, Han, Dianwen, Chen, Bing, Zhao, Wenjing, Yang, Qifeng
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7457819/
https://ncbi.nlm.nih.gov/pubmed/32921987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S253876
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados